IgA Nephropathy Market Size, Share, Growth Report
According to IMARC Group’s latest research report, titled “IgA Nephropathy (IgAN) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033,” A nephropathy (IgAN) refers to a rare autoimmune disease that affects the kidneys. It is characterized by predominant IgA protein deposition and impairment of blood filtration in the kidney’s tiny blood channels. Its symptoms include high blood pressure, little urination, edema, and fatigue. Its diagnosis involves a urine examination to check for the presence of protein or blood in the urine, a blood test to detect the levels of cholesterol, protein, and wastes in the blood, and a glomerular filtration rate (GFR) test to determine how well the kidneys filter waste from the body and kidney biopsy to check if any IgA antibody is present in the glomerulus to aid the body in fighting this sickness. It can be treated using various alternatives, such as antihypertensive drugs, immunosuppressants, and diuretics.
Get Free Sample Copy of Report at – https://www.imarcgroup.com/iga-nephropathy-market/requestsample
Global IgA Nephropathy Market Growth:
The rising prevalence of chronic glomerular diseases is driving the IgA nephropathy (IgAN) market. Moreover, the increasing health awareness and the widespread adoption of supportive measures, including lifestyle modification, including dietary sodium and protein restriction, smoking cessation, weight control, and regular exercise by the masses, is augmenting the market. Apart from this, increasing investments by the governments to advance the healthcare infrastructure is propelling the market favorably. Additionally, the growing number of government initiatives to spread awareness and the rising geriatric population are acting as other growth-inducing factors. Besides, the emergence of regenerative medicine and the growing utilization of telemedicine across the healthcare sector is fostering the market.
Furthermore, several key players are heavily investing in clinical trials for a better understanding of the disease pathophysiology and developing IgAN therapies for slowing the disease progression and managing symptoms, such as high blood pressure, protein in the urine, and swelling, which is providing a boost to the demand. In line with this, the development of new and innovative treatments for IgAN, including biologics and immunosuppressants, is helping to improve patient outcomes, acting as other growth-inducing factors. Additionally, the rising adoption of home-based dialysis is providing convenience and cost-effectiveness to patients, which is impacting the market favorably. Other factors, including continual technological advancements in diagnostic tests for kidney diseases and extensive research and development (R&D) activities by leading players, are creating a positive market outlook.
Key Market Segmentation:
Time Period of the Study:
- Base Year: 2022
- Historical Period: 2017-2022
- Market Forecast: 2023-2033
Analysis Covered Across Each Country:
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the igA nephropathy (IgAN) market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the igA nephropathy (IgAN) market
- Reimbursement scenario in the market
- In-market and pipeline drugs
In-Market Drugs:
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs:
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Regulatory Status
Countries Covered:
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Key Highlights of the Report:
- Market Performance
- Market Outlook
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
